ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36535
0.00%
Bitcoin
67,545.57
0.10%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. aTyr Pharma Inc (LIFE)

  7. aTyr Pharma Inc (LIFE) News

LIFE

aTyr Pharma (LIFE)

aTyr Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIFE
DateTimeSourceHeadlineSymbolCompany
05/29/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
05/24/20243:00PMGlobeNewswire Inc.aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LIFEaTyr Pharma Inc
05/23/20246:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
05/23/20246:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
05/23/20246:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
05/23/20246:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
05/15/20246:00AMGlobeNewswire Inc.aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceNASDAQ:LIFEaTyr Pharma Inc
05/14/20247:00AMGlobeNewswire Inc.aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:LIFEaTyr Pharma Inc
05/06/20247:00AMGlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
05/02/20243:00PMGlobeNewswire Inc.aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
04/01/20247:00AMGlobeNewswire Inc.aTyr Pharma to Participate in April Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
03/14/20243:00PMGlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
02/28/20247:00AMGlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsNASDAQ:LIFEaTyr Pharma Inc
02/21/20247:00AMGlobeNewswire Inc.aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsNASDAQ:LIFEaTyr Pharma Inc
02/06/20247:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
02/06/20247:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
01/29/20247:00AMGlobeNewswire Inc.aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityNASDAQ:LIFEaTyr Pharma Inc
01/18/20247:00AMGlobeNewswire Inc.aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorNASDAQ:LIFEaTyr Pharma Inc
01/09/20246:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
01/09/20246:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
01/02/202411:21AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIFEaTyr Pharma Inc
12/12/20235:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
11/20/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIFEaTyr Pharma Inc
11/13/20233:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
11/13/20237:00AMGlobeNewswire Inc.aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023NASDAQ:LIFEaTyr Pharma Inc
11/09/20234:01PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIFEaTyr Pharma Inc
11/09/20233:42PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIFEaTyr Pharma Inc
11/09/20233:11PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIFEaTyr Pharma Inc
11/09/20233:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
11/09/20233:00PMGlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LIFE

Your Recent History

USOTC
HMBL
HUMBL (PK)
AMEX
FOXO
FOXO Technologies
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
DRNK
NoHo (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
GNCP
GNCC Capital (CE)
NASDAQ
COOP
Mr Cooper
USOTC
IFUS
Impact Fusion (PK)
NASDAQ
NB
NioCorp Developments
USOTC
CEOS
CeCors (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
RVNC
Revance Therapeutics
USOTC
FSRN
Fisker (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved